Acquisitions - Preliminary Fair Value of Purchase Consideration (Details) - USD ($)		6 Months Ended
	Apr. 18, 2022	Jun. 30, 2022
Business Acquisition [Line Items]
Total estimated purchase consideration		$ 45,953,685
Elusys Therapeutics
Business Acquisition [Line Items]
Cash consideration	$ 3,000,000
Deferred cash consideration	2,000,000
Earn out	7,400,000
Additional earn out	4,735,000
Receivable consideration	22,318,685
Contract deferred Consideration	6,500,000
Total estimated purchase consideration	$ 45,953,685